Complete Filing Data
MIRA PHARMACEUTICALS, INC. reported Net Income Loss of -$10.44 million for FY2025.
All values from 10-K, 20-F, and 10-Q filings on SEC EDGAR, organized by financial statement. Scroll each table horizontally for the full history. Blank cells mean MIRA PHARMACEUTICALS, INC. did not report that metric for that period in XBRL — often because accounting standards changed which tag a company files under (for example, most companies moved revenue to the ASC-606 tag in 2018), so a metric may continue in a different row. Rows marked * merge those successor tags into one continuous series, preferring the audited value from the newest-standard tag where periods overlap.
Income Statement
Annual (10-K / 20-F)
| Metric \ Fiscal Year | FY2025 | FY2024 | FY2023 | FY2022 |
|---|---|---|---|---|
| Net Income Loss | -$10.4M | -$7.9M | -$12.0M | -$7.1M |
| Operating Expenses | $10.5M | $8.0M | $8.5M | $7.0M |
| General And Administrative Expense | $8.8M | $4.7M | $6.5M | $3.0M |
| Research And Development Expense | $1.7M | $3.3M | $1.6M | $2.4M |
| Interest Expense | -$165.7K | $3.5M | $10.3K | |
| Interest Expense Net | $3.5M | $10.3K | ||
| Net Income Loss Available To Common Stockholders Basic | -$32.0M | -$7.9M | ||
| Interest Income Expense Net | $98.9K | $165.7K | ||
| Research And Development Offset Cost Incurred | ||||
| Other Nonoperating Income Expense | $50.6K | $165.7K | ||
| Nonoperating Income Expense | ||||
| Other Nonoperating Expense | $13.1K |
Quarterly (10-Q, single quarters)
| Metric \ Quarter | Q3 2025 | Q2 2025 | Q1 2025 | Q3 2024 | Q2 2024 | Q1 2024 | Q3 2023 | Q2 2023 | Q1 2023 | Q3 2022 | Q2 2022 | Q1 2022 |
|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Net Income Loss | -$1.1M | -$1.5M | -$1.8M | -$2.0M | -$1.7M | -$1.7M | -$3.6M | -$1.3M | -$1.3M | -$1.8M | -$2.4M | -$1.5M |
| Operating Expenses | $1.3M | $1.5M | $1.8M | $2.1M | $1.7M | $1.8M | $3.2M | $970.2K | $1.3M | $1.8M | $2.4M | |
| General And Administrative Expense | $904.3K | $1.0M | $1.5M | $1.0M | $1.1M | $1.0M | $2.1M | $1.1M | $614.2K | $736.1K | $1.6M | |
| Research And Development Expense | $412.6K | $496.2K | $314.4K | $1.1M | $614.5K | $762.3K | $1.0M | -$101.0K | $271.6K | $715.0K | ||
| Interest Expense | -$21.4K | -$37.8K | -$39.4K | -$50.4K | $427.7K | $295.9K | $1.7K | $2.3K | $2.3K | |||
| Interest Expense Net | $1.7K | |||||||||||
| Net Income Loss Available To Common Stockholders Basic | -$22.7M | -$2.0M | ||||||||||
| Interest Income Expense Net | $15.7K | $37.8K | ||||||||||
| Research And Development Offset Cost Incurred | $101.0K | -$269.4K | ||||||||||
| Other Nonoperating Income Expense | -$107.00 | |||||||||||
| Nonoperating Income Expense | $179.3K | $37.8K | ||||||||||
| Other Nonoperating Expense | $12.4K |
Balance Sheet
Annual (10-K / 20-F)
| Metric \ Fiscal Year | FY2025 | FY2024 | FY2023 | FY2022 | FY2021 |
|---|---|---|---|---|---|
| Stockholders Equity * | $10.4M | $2.2M | $4.4M | -$596.2K | $2.3M |
| Cash Cash Equivalents Restricted Cash And Restricted Cash Equivalents Including Disposal Group And Discontinued Operations | $6.3M | $2.8M | $4.6M | $351.0K | $2.8M |
| Cash Cash Equivalents Restricted Cash And Restricted Cash Equivalents Period Increase Decrease Including Exchange Rate Effect | $3.5M | -$1.8M | $4.3M | -$2.5M | |
| Retained Earnings Accumulated Deficit | -$39.6M | -$29.1M | -$21.3M | -$9.3M | |
| Liabilities Current | $702.1K | $723.3K | $558.1K | $1.4M | |
| Liabilities And Stockholders Equity | $11.1M | $2.9M | $4.9M | $858.1K | |
| Liabilities | $702.1K | $723.3K | $558.1K | $1.5M | |
| Common Stock Value | $4.2K | $1.7K | $1.5K | $6.7K | |
| Assets Current | $11.1M | $2.9M | $4.9M | $494.4K | |
| Assets | $11.1M | $2.9M | $4.9M | $858.1K | |
| Cash | $6.3M | $2.8M | |||
| Payment Of Deferred Offering Costs | $292.5K | -$143.4K | $43.4K | ||
| Accounts Payable And Accrued Liabilities Current | $723.3K | $538.6K | $811.7K | ||
| Accounts Payable Current | $129.2K | $723.3K | |||
| Cash And Cash Equivalents At Carrying Value | $6.3M | $2.8M | |||
| Operating Lease Right Of Use Asset | $5.1K | $200.0K | |||
| Operating Lease Liability Noncurrent | $84.3K | ||||
| Increase Decrease Right Of Use Lease Net | -$5.5K | $5.5K | |||
| Other Receivables Net Current | $11.9K | ||||
| Operating Lease Liability Current | $5.1K | ||||
| Deferred Costs Current | $143.4K | ||||
| Related Party Accounts Payable | |||||
| Adjustments To Additional Paid In Capital Collection Of Stock Subscription Receivable | |||||
| Accrued Liabilities Current | |||||
| Unrealized Gain Loss On Investments | -$35.2K | ||||
| Preferred Stock Dividends Income Statement Impact | $21.6M | ||||
| Deferred Offering Costs Charged To Additional Paidin Capital | $32.5K | $426.3K | |||
| Deferred Finance Costs Net |
Quarterly (10-Q, single quarters)
| Metric \ Quarter | Q3 2025 | Q2 2025 | Q1 2025 | Q4 2024 | Q3 2024 | Q2 2024 | Q1 2024 | Q4 2023 | Q3 2023 | Q2 2023 | Q1 2023 | Q4 2022 | Q3 2022 | Q2 2022 | Q1 2022 |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Stockholders Equity * | $7.5M | $569.9K | $1.3M | $3.6M | $2.2M | $3.2M | $4.4M | $8.1M | $1.2M | -$1.8M | -$596.2K | $320.4K | $1.1M | $2.4M | |
| Cash Cash Equivalents Restricted Cash And Restricted Cash Equivalents Including Disposal Group And Discontinued Operations | $2.6M | $730.5K | $1.2M | $4.1M | $2.8M | $3.5M | $5.9M | $24.8K | $1.3K | $187.4K | $826.0K | ||||
| Cash Cash Equivalents Restricted Cash And Restricted Cash Equivalents Period Increase Decrease Including Exchange Rate Effect | -$1.6M | -$1.1M | -$349.6K | ||||||||||||
| Retained Earnings Accumulated Deficit | -$33.6M | -$32.5M | -$30.9M | -$26.7M | -$24.7M | -$23.0M | -$15.5M | -$11.9M | |||||||
| Liabilities Current | $83.9K | $298.5K | $106.2K | $692.8K | $796.6K | $652.0K | $868.4K | $2.6M | |||||||
| Liabilities And Stockholders Equity | $7.6M | $868.3K | $1.4M | $4.3M | $3.0M | $3.8M | $9.0M | $3.8M | |||||||
| Liabilities | $83.9K | $298.5K | $106.2K | $692.8K | $796.6K | $652.0K | $902.9K | $2.6M | |||||||
| Common Stock Value | $4.0K | $1.7K | $1.7K | $1.6K | $1.5K | $1.5K | $1.5K | $6.7K | |||||||
| Assets Current | $7.6M | $832.9K | $1.4M | $4.2M | $2.9M | $3.7M | $6.1M | $420.7K | |||||||
| Assets | $7.6M | $868.3K | $1.4M | $4.3M | $3.0M | $3.8M | $9.0M | $3.8M | |||||||
| Cash | $2.6M | $730.5K | $1.2M | ||||||||||||
| Payment Of Deferred Offering Costs | $46.3K | ||||||||||||||
| Accounts Payable And Accrued Liabilities Current | $692.8K | $782.1K | $779.6K | $659.1K | |||||||||||
| Accounts Payable Current | $83.9K | $298.5K | $100.7K | $636.3K | $538.6K | ||||||||||
| Cash And Cash Equivalents At Carrying Value | $2.6M | $730.5K | $1.2M | ||||||||||||
| Operating Lease Right Of Use Asset | $1.3K | ||||||||||||||
| Operating Lease Liability Noncurrent | $34.5K | $51.5K | |||||||||||||
| Increase Decrease Right Of Use Lease Net | |||||||||||||||
| Other Receivables Net Current | |||||||||||||||
| Operating Lease Liability Current | $1.3K | ||||||||||||||
| Deferred Costs Current | $353.4K | ||||||||||||||
| Related Party Accounts Payable | $116.4K | ||||||||||||||
| Adjustments To Additional Paid In Capital Collection Of Stock Subscription Receivable | $135.0K | ||||||||||||||
| Accrued Liabilities Current | $5.5K | $300.0K | |||||||||||||
| Unrealized Gain Loss On Investments | $176.1K | ||||||||||||||
| Preferred Stock Dividends Income Statement Impact | $21.6M | ||||||||||||||
| Deferred Offering Costs Charged To Additional Paidin Capital | |||||||||||||||
| Deferred Finance Costs Net | $2.8M | $3.2M |
Cash Flow Statement
Annual (10-K / 20-F)
| Metric \ Fiscal Year | FY2025 | FY2024 | FY2023 | FY2022 |
|---|---|---|---|---|
| Net Cash Provided By Used In Operating Activities | -$4.7M | -$5.6M | -$4.5M | -$5.6M |
| Net Cash Provided By Used In Financing Activities | $8.2M | $3.8M | $8.8M | $3.1M |
| Increase Decrease In Accounts Payable And Accrued Liabilities | -$594.1K | $184.8K | -$389.5K | $152.1K |
| Share Based Compensation | $6.3M | $1.9M | $2.6M | $1.3M |
| Increase Decrease In Prepaid Expense | -$26.6K | -$189.1K | $243.8K | |
| Payments For Proceeds From Affiliates Advances | -$33.7K | $69.2K | -$445.6K | |
| Proceeds From Issuance Of Common Stock | $7.0M | $3.6M | $7.7M | $2.9M |
| Increase Decrease In Other Receivables | -$11.9K | $11.9K | ||
| Proceeds From Bayshore Trust Shortswing Disgorgement | $148.7K |
Quarterly (10-Q, single quarters)
| Metric \ Quarter | Q1 2025 | Q1 2024 | Q1 2023 |
|---|---|---|---|
| Net Cash Provided By Used In Operating Activities | -$1.6M | -$1.0M | -$1.1M |
| Net Cash Provided By Used In Financing Activities | $3.4K | -$24.3K | $725.7K |
| Increase Decrease In Accounts Payable And Accrued Liabilities | -$617.2K | $97.7K | $176.3K |
| Share Based Compensation | $874.8K | $500.2K | $147.8K |
| Increase Decrease In Prepaid Expense | $103.9K | -$58.5K | $60.0K |
| Payments For Proceeds From Affiliates Advances | $24.3K | -$685.5K | |
| Proceeds From Issuance Of Common Stock | $3.4K | ||
| Increase Decrease In Other Receivables | -$11.9K | ||
| Proceeds From Bayshore Trust Shortswing Disgorgement |
Per-Share & Share Counts
Annual (10-K / 20-F)
| Metric \ Fiscal Year | FY2025 | FY2024 | FY2023 | FY2022 |
|---|---|---|---|---|
| Weighted Average Number Of Shares Outstanding Basic | 23.7M | 15.4M | 13.9M | 17.6M |
| Earnings Per Share Diluted | $-1.35 | $-0.51 | $-0.85 | $-0.40 |
| Earnings Per Share Basic | $-1.35 | $-0.51 | $-0.85 | $-0.40 |
| Weighted Average Number Of Diluted Shares Outstanding | 15.4M | 13.9M | 17.6M | |
| Common Stock Par Or Stated Value Per Share | $0.00 | $0.00 | $0.00 | $0.00 |
| Preferred Stock Shares Outstanding | 0.00 | 0.00 | 0.00 | 0.00 |
| Preferred Stock Shares Issued | 0.00 | 0.00 | 0.00 | 0.00 |
| Preferred Stock Shares Authorized | 10.0M | 10.0M | 10.0M | 10.0M |
| Preferred Stock Par Or Stated Value Per Share | $0.00 | $0.00 | $0.00 | $0.00 |
| Common Stock Shares Outstanding | 41.9M | 16.6M | 14.8M | 13.3M |
| Common Stock Shares Issued | 41.9M | 16.6M | 14.8M | 13.3M |
| Common Stock Shares Authorized | 100.0M | 100.0M | 100.0M | 100.0M |
Quarterly (10-Q, single quarters)
| Metric \ Quarter | Q3 2025 | Q2 2025 | Q1 2025 | Q3 2024 | Q2 2024 | Q1 2024 | Q3 2023 | Q2 2023 | Q1 2023 | Q3 2022 | Q2 2022 |
|---|---|---|---|---|---|---|---|---|---|---|---|
| Weighted Average Number Of Shares Outstanding Basic | 19.3M | 17.0M | 16.6M | 15.1M | 14.8M | 14.8M | 13.6M | 13.3M | 17.8M | 13.2M | 13.1M |
| Earnings Per Share Diluted | $-1.18 | $-0.09 | $-0.11 | $-0.14 | $-0.11 | $-0.15 | $-0.26 | $-0.10 | $-0.10 | $-0.14 | $-0.19 |
| Earnings Per Share Basic | $-1.18 | $-0.09 | $-0.11 | $-0.14 | $-0.11 | $-0.15 | $-0.26 | $-0.10 | $-0.10 | $-0.14 | $-0.19 |
| Weighted Average Number Of Diluted Shares Outstanding | 19.3M | 17.0M | 16.6M | 15.1M | 14.8M | 14.8M | 13.6M | 13.3M | 17.8M | 13.2M | 13.1M |
| Common Stock Par Or Stated Value Per Share | $0.00 | $0.00 | $0.00 | $0.00 | $0.00 | $0.00 | $0.00 | ||||
| Preferred Stock Shares Outstanding | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | |||
| Preferred Stock Shares Issued | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | |||
| Preferred Stock Shares Authorized | 10.0M | 10.0M | 10.0M | 10.0M | 10.0M | 10.0M | 10.0M | 10.0M | |||
| Preferred Stock Par Or Stated Value Per Share | $0.00 | $0.00 | $0.00 | $0.00 | $0.00 | $0.00 | $0.00 | $0.00 | |||
| Common Stock Shares Outstanding | 39.5M | 17.4M | 16.8M | 16.3M | 14.8M | 14.8M | 14.8M | 13.3M | |||
| Common Stock Shares Issued | 39.5M | 17.4M | 16.8M | 16.3M | 14.8M | 14.8M | 14.8M | 13.3M | |||
| Common Stock Shares Authorized | 100.0M | 100.0M | 100.0M | 100.0M | 100.0M | 100.0M | 100.0M | 100.0M |
Other Metrics
Annual (10-K / 20-F)
| Metric \ Fiscal Year | FY2025 | FY2024 | FY2023 | FY2022 |
|---|---|---|---|---|
| Adjustments To Additional Paid In Capital Sharebased Compensation Requisite Service Period Recognition Value | $6.0M | $1.9M | $2.6M | $1.3M |
| Additional Paid In Capital | $50.0M | $31.3M | $25.7M | $8.7M |
| Prepaid Expense Current | $28.1K | $54.7K | $243.8K | |
| Stock Issued During Period Value Other | $6.7M | $3.6M | $2.9M | |
| Related Party Travel Costs | $453.6K | $1.7M | ||
| Repayments Of Long Term Lines Of Credit | $1.1M | $160.0K | ||
| Stock Issued During Period Value New Issues | $250.0K | |||
| Adjustments To Additional Paid In Capital Warrant Issued | $5.3M | |||
| Amortization Of Financing Costs | $732.3K | |||
| Adjustments To Additional Paid In Capital Payment Of Short Swing Disgorgement By Bay Shore Trust | $148.7K | |||
| Stock Issued During Period Value Conversion Of Convertible Securities | $1.1M | |||
| Stock Issued During Period Value Issued For Services | $184.4K | $7.7M | ||
| Stock Issued During Period Shares New Issues | 1.3M | |||
| Interest Income | ||||
| Stock Issued During Period Value Initial Public Offering | $7.7M |
Quarterly (10-Q, single quarters)
| Metric \ Quarter | Q3 2025 | Q2 2025 | Q1 2025 | Q3 2024 | Q2 2024 | Q1 2024 | Q3 2023 | Q2 2023 | Q1 2023 | Q3 2022 | Q2 2022 | Q1 2022 |
|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Adjustments To Additional Paid In Capital Sharebased Compensation Requisite Service Period Recognition Value | $297.1K | $489.6K | $874.8K | $269.0K | $604.8K | $500.2K | $1.5M | $737.2K | $147.8K | $147.8K | $1.0M | |
| Additional Paid In Capital | $41.1M | $33.0M | $32.2M | $30.3M | $26.9M | $26.2M | $23.6M | $13.1M | ||||
| Prepaid Expense Current | $61.9K | $102.4K | $158.6K | $86.6K | $108.6K | $185.3K | $202.8K | $42.5K | ||||
| Stock Issued During Period Value Other | $323.8K | $3.4K | $3.1M | $147.8K | $900.0K | $1.6M | ||||||
| Related Party Travel Costs | $453.6K | $357.4K | $560.8K | |||||||||
| Repayments Of Long Term Lines Of Credit | ||||||||||||
| Stock Issued During Period Value New Issues | $2.7M | $323.8K | $3.4K | $3.1M | $250.0K | |||||||
| Adjustments To Additional Paid In Capital Warrant Issued | $3.5M | |||||||||||
| Amortization Of Financing Costs | ||||||||||||
| Adjustments To Additional Paid In Capital Payment Of Short Swing Disgorgement By Bay Shore Trust | $148.7K | |||||||||||
| Stock Issued During Period Value Conversion Of Convertible Securities | $1.1M | |||||||||||
| Stock Issued During Period Value Issued For Services | $7.7M | |||||||||||
| Stock Issued During Period Shares New Issues | ||||||||||||
| Interest Income | $8.5K | $39.4K | ||||||||||
| Stock Issued During Period Value Initial Public Offering | $7.7M |
Most recent annual filing with the SEC: March 31, 2026
Data sourced from SEC EDGAR public filings as of August 8, 2026.